There is new hope on the horizon for more randomized trials in patients with kidney disease. The kidney is moving into the foreground of clinical research and patients with advanced kidney disease are no longer systematically excluded from prospective cardiovascular outcome trials as they have been in the past.1 As the results are published, opportunities emerge for secondary analyses to better understand trial results and generate novel hypotheses from prespecified research questions. However, new evaluation tools and scoring metrics are necessary.